Displaying drugs 15451 - 15475 of 15530 in total
3-Phenylpropylamine
Experimental
2,5-di-tert-butylhydroquinone
Experimental
5-PENTYL-2-PHENOXYPHENOL
Experimental
N-methyl-1-(2-thiophen-2-ylphenyl)methanamine
Experimental
4,4'-Dihydroxybenzophenone
Experimental
1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE
Experimental
2,6-dibromo-4-phenoxyphenol
Experimental
5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole
5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. 5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole targets the protein genome polyprotein.
Experimental
Henagliflozin
Henagliflozin has been used in trials studying the treatment of Type 2 Diabetes.
Investigational
Tolpropamine
Experimental
Suloctidil
Experimental
Eprozinol
Experimental
Etybenzatropine
Experimental
Tiocarlide
Experimental
Quifenadine
Experimental
Penfluridol
Experimental
XMT-1001
XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). XMT-1001 has demonstrated an improved therapeutic...
Investigational
Matched Description: … XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human …
NV-18
NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. …
6-Methylamino-5-Nitroisocytosine
Experimental
Displaying drugs 15451 - 15475 of 15530 in total